Skip to content
    Reviews

    Transurethral ultrasound ablation (TULSA) for prostate cancer: a systematic review and meta-analysis

    Wang et alBJU international

    Transurethral ultrasound ablation (TULSA) for prostate cancer: a systematic review and meta-analysis
    A systematic review and meta-analysis evaluated the oncological, functional, and safety outcomes of magnetic resonance imaging-guided transurethral ultrasound ablation (TULSA) in 630 patients across 12 studies. Among the cohort, 563 patients (89%) underwent primary TULSA, 57 (9%) underwent salvage TULSA, and 10 (2%) received palliative treatment.
    At 12 months, the pooled biopsy-proven clinically significant prostate cancer (csPCa) recurrence-free survival (RFS) reached 70% (95% confidence interval [CI] 50–84%) for primary TULSA and 80% (95% CI 66–89%) for salvage procedures. When analyzed by ablation fraction, 12-month csPCa RFS was 75% (95% CI 60–86%) for whole-gland ablation compared to 71% (95% CI 51–86%) for focal ablation.
    Preservation of functional status was favorable, with a pooled pad-free continence rate of 90% (95% CI 71–97%) and an erectile function preservation rate of 81% (95% CI 56–94%) at final follow-up. Grade 3 adverse events occurred in 6% of patients (95% CI 4–11%).
    Substantial heterogeneity was observed across multiple endpoints, attributable to differences in outcome definitions, treatment approaches, and follow-up protocols. While primary TULSA demonstrates acceptable short-term safety and minimal functional morbidity, evidence regarding long-term oncological control remains limited, and procedural modifications remain experimental. Data for salvage TULSA also remain constrained, with preliminary literature noting relatively high rates of incontinence.

    Key Takeaways

    • Pooled 12-month clinically significant prostate cancer recurrence-free survival was 70% (95% CI 50–84%) following primary TULSA and 80% (95% CI 66–89%) following salvage TULSA, with rates of 75% (95% CI 60–86%) for whole-gland ablation and 71% (95% CI 51–86%) for focal ablation.
    • Functional outcomes demonstrated a 90% (95% CI 71–97%) pad-free continence rate and an 81% (95% CI 56–94%) rate of preserved erectile function at last follow-up, alongside a 6% (95% CI 4–11%) incidence of grade 3 adverse events.
    Read the original sourceBJU international